RayKnowChina Research Map
Shortlist

ShanghaiShanghai Jiao Tong University School of Medicine

Shanghai Ninth People's Hospital

上海交通大学医学院附属第九人民医院

Listed for 27 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Shanghai Ninth People's Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌5 papers led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Lung cancer肺癌33 papers led
  4. Pancreatic cancer胰腺癌11 papers led
  5. Breast cancer乳腺癌27 papers led
  6. Glioma胶质瘤9 papers led
  7. Retinoblastoma视网膜母细胞瘤29 papers led
  8. Osteosarcoma骨肉瘤15 papers led
  9. Gastrointestinal stromal tumour胃肠道间质瘤1 paper led
  10. Neuroblastoma神经母细胞瘤2 papers led
  11. Lymphoma淋巴瘤22 papers led1 open trial led
  12. Haemophilia A血友病 A1 paper led
  13. Fanconi anaemia范可尼贫血1 paper led
  14. Coronary heart disease冠心病15 papers led
  15. Congenital heart disease先天性心脏病0 papers led
  16. Scoliosis脊柱侧弯2 papers led
  17. Takayasu arteritis大动脉炎0 papers led
  18. Idiopathic pulmonary fibrosis特发性肺纤维化4 papers led
  19. Spinal muscular atrophy脊髓性肌萎缩症0 papers led
  20. Duchenne muscular dystrophy杜氏肌营养不良1 paper led
  21. Behçet disease白塞病1 paper led
  22. IgA nephropathyIgA 肾病0 papers led
  23. Osteogenesis imperfecta成骨不全症1 paper led
  24. Primary biliary cholangitis原发性胆汁性胆管炎0 papers led
  25. Hirschsprung disease先天性巨结肠0 papers led
  26. Inherited epidermolysis bullosa遗传性大疱性表皮松解症1 paper led
  27. Leber hereditary optic neuropathyLeber 遗传性视神经病变1 paper led

Not listed for: Hepatocellular carcinoma, Stomach cancer, Hepatoblastoma, Chordoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Beta thalassaemia, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Anti-NMDA receptor encephalitis, Hepatic echinococcosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Fabry disease, Pompe disease, Alport syndrome, Gaucher disease, Niemann–Pick disease type C, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hereditary angioedema, Familial adenomatous polyposis, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 5 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
5
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 3320222023: 0020232024: 0020242025: 002025

10 hospitals in Shanghai for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRecurrent / metastatic diseaseImaging & AI
Departments in papersENT / head & neck surgery

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 1120232024: 2220242025: 002025

18 hospitals in Shanghai for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesMolecular markers & genomics
Departments in papersPathology / laboratory medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 33 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.1%.

Papers led
33
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
2
led by another institution
Papers led per year
2021: 101020212022: 8820222023: 4420232024: 5520242025: 442025

22 hospitals in Shanghai for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06127303

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Chest Hospital; 2 listed hospitals as study sitesShanghai

  2. Recruiting
    Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid Tumors
    Phase
    Phase 1/Phase 2
    Started
    2021-09
    Posted
    Registry
    NCT04930432

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 56 listed hospitals as study sitesBeijing, Bengbu, Changchun, Changsha, Chengdu, Chongqing, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Kunming, Lanzhou, Nanchang, Nanjing, Nanning, Nantong, Qingdao, Shanghai, Shantou, Shenyang, Shenzhen, Shijiazhuang, Suzhou, Taiyuan, Taizhou, Tianjin, Weifang, Wenzhou, Wuhan, Xi'an, Xiamen, Xuzhou, Yantai, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicineOphthalmology / neuro-ophthalmology

Over half of these papers are lab or animal studies.

Papers it led33
  1. Social support, health behavior self-efficacy, and anxiety on physical activity levels among lung cancer survivors: a structural equation modeling.2026Journal of cancer survivorship : research and practice
  2. Development of a Machine Learning Algorithm-Based Predictive Model for Physical Activity Levels in Lung Cancer Survivors: A Cross-Sectional Study.2026Journal of clinical nursing
  3. A 7-Year-Old Girl With Multiple Pulmonary Nodules.2025Chest
  4. Analysis of Factors Related to Physical Activity Levels Among Lung Cancer Survivors Who Underwent Nonsurgical Treatment: A Cross-Sectional Study.2025Journal of clinical nursing
  5. A-to-I RNA Edited miR-3167 Restrains Malignant Behaviors of Lung Adenocarcinoma by Influencing SSR2-Meditated Hippo Signaling.2025Molecular carcinogenesis
  6. Evaluation of the risk-benefit of thoracic paravertebral nerve block combined with propofol anesthesia and inhalation combined anesthesia for radical treatment in elderly lung cancer based on diaphragm functional parameters.2025Pakistan journal of pharmaceutical sciences
  7. Economic evaluation of cemiplimab plus chemotherapy regimen for advanced non-small-cell lung cancer.2024BMC cancerFree full text
  8. Tumor-Derived RAB21+ABHD12+ sEVs Drive the Premetastatic Microenvironment in the Lung.2024Cancer immunology research
  9. SNHG12 in cancer-associated fibroblast-derived extracellular vesicle induces macrophage-myofibroblast transition.2024EpigenomicsFree full text
  10. Nasal mRNA Nanovaccine with Key Activators of Dendritic and MAIT Cells for Effective Against Lung Tumor Metastasis in Mice Model.2024International journal of nanomedicineFree full text
  11. Exploring factors associated with postoperative physical activity and sedentary behavior in newly diagnosed lung cancer patients: a cross-sectional study.2024Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  12. LncRNA SNHG12 Decreases Non-Small Cell Lung Cancer Cell Sensitivity to Cisplatin by Repressing miR-525-5p and Promoting XIAP.2023Annals of clinical and laboratory science
  13. Combined all-trans retinoic acid with low-dose apatinib in treatment of recurrent/metastatic head and neck adenoid cystic carcinoma: A single-center, secondary analysis of a phase II study.2023Cancer medicineFree full text
  14. TRAIP serves as a potential prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma.2023International immunopharmacology
  15. Bispecific antibodies targeting EGFR/Notch enhance the response to talazoparib by decreasing tumour-initiating cell frequency.2023TheranosticsFree full text
  16. Exosomes from PM 2.5-treated Human Bronchial Epithelial Cells Increase Lung Cancer Metastatic Potential.2022Biomedical and environmental sciences : BES
  17. circBIRC6 contributes to the development of non-small cell lung cancer via regulating microRNA-217/amyloid beta precursor protein binding protein 2 axis.2022Chinese medical journalFree full text
  18. Skin Metastasis: Rare First Manifestation of Lung Cancer.2022Facial plastic surgery : FPS
  19. Ceritinib (LDK378) prevents bone loss via suppressing Akt and NF-κB-induced osteoclast formation.2022Frontiers in endocrinologyFree full text
  20. Fbxo45-mediated NP-STEP46 degradation via K6-linked ubiquitination sustains ERK activity in lung cancer.2022Molecular oncologyFree full text
  21. Development of mobile health-based self-management support for patients with lung cancer: A stepwise approach.2022Nursing openFree full text
  22. ALK-fusion-positive secondary ameloblastic carcinoma reached complete response after using alectinib.2022Oral oncology
  23. HIF-1α induced NID1 expression promotes pulmonary metastases via the PI3K-AKT pathway in salivary gland adenoid cystic carcinoma.2022Oral oncology
  24. The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis.2021AgingFree full text
  25. Effects of cancer on patients with COVID-19: a systematic review and meta-analysis of 63,019 participants.2021Cancer biology & medicineFree full text
  26. Rab1A promotes IL-4R/JAK1/STAT6-dependent metastasis and determines JAK1 inhibitor sensitivity in non-small cell lung cancer.2021Cancer letters
  27. LACTB suppresses melanoma progression by attenuating PP1A and YAP interaction.2021Cancer letters
  28. Lactate secreted by PKM2 upregulation promotes Galectin-9-mediated immunosuppression via inhibiting NF-κB pathway in HNSCC.2021Cell death & diseaseFree full text
  29. MRI Image Segmentation Model with Support Vector Machine Algorithm in Diagnosis of Solitary Pulmonary Nodule.2021Contrast media & molecular imagingFree full text
  30. Intranasal Administration of Codium fragile Polysaccharide Elicits Anti-Cancer Immunity against Lewis Lung Carcinoma.2021International journal of molecular sciencesFree full text
  31. ESM1/HIF‑1α pathway modulates chronic intermittent hypoxia‑induced non‑small‑cell lung cancer proliferation, stemness and epithelial‑mesenchymal transition.2021Oncology reports
  32. Chondroitin sulfate modified and adriamycin preloaded hybrid nanoparticles for tumor-targeted chemotherapy of lung cancer.2021The Kaohsiung journal of medical sciencesFree full text
  33. The reversal of drug resistance by two-dimensional titanium carbide Ti2 C (2D Ti2C) in non-small-cell lung cancer via the depletion of intracellular antioxidant reserves.2021Thoracic cancerFree full text
All its trials on ClinicalTrials.gov, any status2
  1. Toripalimab Combined With Cryoablation for First-line Oligo-progression in Driver-negative Advanced NSCLCRecruitingNCT06127303Study sitePhase 2Start 2024-04
  2. Study of MCLA-129, a Human Bispecific EGFR and cMet Antibody, in Patients With Advanced NSCLC and Other Solid TumorsRecruitingNCT04930432Study sitePhase 1/Phase 2Start 2021-09

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 11 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
11
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 3320222023: 2220232024: 1120242025: 112025

19 hospitals in Shanghai for pancreatic cancer192 hospitals in China for pancreatic cancer

No open trial on pancreatic cancer lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncologyPathology / laboratory medicineRadiology / nuclear medicineGastroenterology / hepatology
Papers it led11
  1. OFD1 inhibition induces BRCAness to create a therapeutic vulnerability to PARP inhibition in pancreatic cancer.2025Nature communicationsFree full text
  2. ISG15 Promotes Progression and Gemcitabine Resistance of Pancreatic Cancer Cells Through ATG7.2024International journal of biological sciencesFree full text
  3. A case report of huge pancreas mucinous cystic neoplasm during pregnancy: How doctors think.2023Medicine
  4. PTTG1 Enhances Oncolytic Adenovirus 5 Entry into Pancreatic Adenocarcinoma Cells by Increasing CXADR Expression.2023VirusesFree full text
  5. Modulating cancer-stroma crosstalk by a nanoparticle-based photodynamic method to pave the way for subsequent therapies.2022Biomaterials
  6. METTL3 promotes the growth and metastasis of pancreatic cancer by regulating the m6A modification and stability of E2F5.2022Cellular signalling
  7. Exosome-delivered CD44v6/C1QBP complex drives pancreatic cancer liver metastasis by promoting fibrotic liver microenvironment.2022Gut
  8. Pancreatic tuberculosis: a clinical diagnostic challenge.2021ANZ journal of surgery
  9. lncRNA ANRIL aggravates the chemoresistance of pancreatic cancer cells to gemcitabine by targeting inhibition of miR-181a and targeting HMGB1-induced autophagy.2021AgingFree full text
  10. The RNA methyltransferase NSUN6 suppresses pancreatic cancer development by regulating cell proliferation.2021EBioMedicineFree full text
  11. Formulation Comprising Arsenic Trioxide and Dimercaprol Enhances Radiosensitivity of Pancreatic Cancer Xenografts.2021Technology in cancer research & treatmentFree full text

Run the PubMed searchClinicalTrials.gov

Cancer

Breast cancer

乳腺癌

Led 27 of the 16,974 English-language PubMed papers on breast cancer with an author in mainland China, 2021–2025: 0.2%.

Papers led
27
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 5520212022: 111120222023: 6620232024: 1120242025: 442025

19 hospitals in Shanghai for breast cancer219 hospitals in China for breast cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    A Study of YL202 in Selected Patients With Advanced Solid Tumors
    Phase
    Phase 2
    Started
    2023-12
    Posted
    Registry
    NCT06107686

    Age 18 years to 75 years (registered criteria)

    Lead sponsor is not a listed hospital; 45 listed hospitals as study sitesBeijing, Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Guilin, Hangzhou, Harbin, Hefei, Jinan, Meizhou, Nanchang, Nanning, Qingdao, Shanghai, Shantou, Shenyang, Suzhou, Taiyuan, Taizhou, Urumqi, Weifang, Wuhan, Xi'an, Xiangyang, Xuzhou, Zhengzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersRadiation oncologySurgery (general/hepatobiliary/pancreatic)Pathology / laboratory medicineMedical oncology
Papers it led27
  1. Prognostic significance of CD8 + tumor-infiltrating lymphocytes in operable breast cancer: a meta-analysis.2025BMC cancerFree full text
  2. Effects of sufentanil on immune response, pain mediators and brain-sparing effect in patients with breast cancer undergoing radical mastectomy.2025BMC surgeryFree full text
  3. Adipose-derived stem cells enhance the tumorigenic potential of pre-malignant breast epithelial cells through paracrine activation of PI3K-AKT pathway.2025Breast cancer (Tokyo, Japan)Free full text
  4. Combining ultrasound gray scale ratio and BI-RADS grading for differentiating benign and malignant breast masses.2025Clinical hemorheology and microcirculation
  5. Unlocking the potential of extracellular vesicle circRNAs in breast cancer: From molecular mechanisms to therapeutic horizons.2024Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
  6. Medical Insurance Needs to Include Breast Reconstruction.2023Annals of plastic surgery
  7. Cost-effectiveness of sacituzumab govitecan versus chemotherapy in advanced or metastatic triple-negative breast cancer.2023Breast (Edinburgh, Scotland)Free full text
  8. Integrative pan-cancer analysis of cuproplasia-associated genes for the genomic and clinical characterization of 33 tumors.2023Chinese medical journalFree full text
  9. The prognostic value and biological functions of HFM1 in breast cancer.2023Epigenomics
  10. Comparative Proteomic Analysis of Irradiation-Induced Radioresistant Breast Cancer Cells Using Label-Free Quantitation.2023Frontiers in bioscience (Landmark edition)
  11. Detection of lineage-reprogramming efficiency of tumor cells in a 3D-printed liver-on-a-chip model.2023TheranosticsFree full text
  12. Efficient Magnetic Nanocatalyst-Induced Chemo- and Ferroptosis Synergistic Cancer Therapy in Combination with T1-T2 Dual-Mode Magnetic Resonance Imaging Through Doxorubicin Delivery.2022ACS applied materials & interfaces
  13. Budget Impact Analysis of the Introduction of a Trastuzumab Biosimilar for HER2-Positive Breast Cancer in China.2022Clinical drug investigation
  14. A comprehensive bioinformatic analysis of RanBP9 expression and its relation to prognosis in human breast cancer.2022Epigenomics
  15. Landscape of Artificial Intelligence in Breast Cancer (2000-2021): A Bibliometric Analysis.2022Frontiers in bioscience (Landmark edition)
  16. Association of Adiposity With Mortality Among Black Patients With Breast Cancer.2022JAMA oncology
  17. Atypical/unbalanced ETV6/NTRK3 rearrangement in salivary secretory carcinoma with a focus on the incidence, the patterns, and the clinical implications.2022Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  18. TRIM35 functions as a novel tumor suppressor in breast cancer by inducing cell apoptosis through ubiquitination of PDK1.2022Neoplasma
  19. Anterior Gradient 2 is a Significant Prognostic Biomarker in Bone Metastasis of Breast Cancer.2022Pathology oncology research : PORFree full text
  20. Comment on: Outcomes after breast-conserving surgery or mastectomy in patients with triple-negative breast cancer: meta-analysis.2022The British journal of surgery
  21. Exploring the Value of Additional Primary Tumour Excision Combined with Systemic Therapy Administered in Different Sequences for Patients with de Novo Metastatic Breast Cancer.2022The breast journalFree full text
  22. Development and validation of an extended Cox prognostic model for patients with ER/PR+ and HER2- breast cancer: a retrospective cohort study.2022World journal of surgical oncologyFree full text
  23. Atezolizumab Plus Chemotherapy vs. Chemotherapy in Advanced or Metastatic Triple-Negative Breast Cancer: A Cost-Effectiveness Analysis.2021Frontiers in public healthFree full text
  24. Regulating the immunosuppressive tumor microenvironment to enhance breast cancer immunotherapy using pH-responsive hybrid membrane-coated nanoparticles.2021Journal of nanobiotechnologyFree full text
  25. Graphene-modified CePO4 nanorods effectively treat breast cancer-induced bone metastases and regulate macrophage polarization to improve osteo-inductive ability.2021Journal of nanobiotechnologyFree full text
  26. Mindfulness-based interventions for breast cancer patients in China across outcome domains: a systematic review and meta-analysis of the Chinese literature.2021Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
  27. Application of a second opinion ultrasound in Breast Imaging Reporting and Data System 4A cases: can immediate biopsy be avoided?2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)1
  1. [Effectiveness of lobulated pedicled rectus abdominis myocutaneous flap for repairing huge chest wall defect].2023Zhongguo xiu fu chong jian wai ke za zhi = Zhongguo xiufu chongjian waike zazhi = Chinese journal of reparative and reconstructive surgeryFree full text
All its trials on ClinicalTrials.gov, any status6
  1. A Study of YL202 in Selected Patients With Advanced Solid TumorsRecruitingNCT06107686Study sitePhase 2Start 2023-12
  2. Study to Evaluate Safety and Efficacy of TJ107 Combine With PD-1 in Patients With Solid TumorsStatus unknownNCT05145907Study sitePhase 2Start 2021-12
  3. A Study of T3011 Administered Via Intratumoral Injection in Patients With Advanced Solid TumorsStatus unknownNCT05602792Study sitePhase 1/Phase 2Start 2020-04
  4. Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid TumorsStatus unknownNCT04450732Study sitePhase 1Start 2020-07
  5. Hypofractionated Vs Conventional Fractionated Postmastectomy Radiotherapy for High Risk Breast CancerCompletedNCT03856372Study siteN/AStart 2018-09
  6. Adjuvant Treatment of EC Followed by Taxane +/- Carboplatin in Triple-Negative Breast CancerActive, not recruitingNCT02455141Study sitePhase 3Start 2016-03

Run the PubMed searchClinicalTrials.gov

Cancer

Glioma

胶质瘤

Led 9 of the 7,081 English-language PubMed papers on glioma with an author in mainland China, 2021–2025: 0.1%.

Papers led
9
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 1120222023: 1120232024: 4420242025: 222025

17 hospitals in Shanghai for glioma187 hospitals in China for glioma

No open trial on glioma lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersPathology / laboratory medicineNeurosurgeryOphthalmology / neuro-ophthalmology

Over half of these papers are lab or animal studies.

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 29 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 9.6%.

Papers led
29
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 4420212022: 6620222023: 5520232024: 6620242025: 882025

11 hospitals in Shanghai for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology
Papers it led29
  1. Status of and factors influencing paternal fatigue in children with retinoblastoma: a cross-sectional study.2025BMC cancerFree full text
  2. Factors influencing delayed medical treatment in children with retinoblastoma: a qualitative study.2025BMC cancerFree full text
  3. Anxiety, depression and fear of disease progression among Chinese parents of children with retinoblastoma.2025BMC psychiatryFree full text
  4. Lactylation-boosted polycomb repression of KLF4 elicits glycolysis in retinoblastoma: A positive feedback circuit between histone modifications.2025Cancer letters
  5. Spatial Proteomic Analysis Highlights Molecular Reprogramming in Optic Nerve Invasive Retinoblastoma.2025Investigative ophthalmology & visual scienceFree full text
  6. Aurora A Kinase Inhibition Is Synthetic Lethal With the Activation of MYCN in Retinoblastoma.2025Investigative ophthalmology & visual scienceFree full text
  7. Increased clinical risk factors and absence of leucocoria in late-onset retinoblastoma: a comparative cohort study.2025The British journal of ophthalmology
  8. Effect of intra-arterial chemotherapy drug regimens on globe salvage outcomes of retinoblastoma patients.2025The British journal of ophthalmologyFree full text
  9. Does vitreous haemorrhage and calcification lead to increased risk of enucleation in advanced retinoblastoma?2024Acta ophthalmologica
  10. Recent progress in retinoblastoma: Pathogenesis, presentation, diagnosis and management.2024Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
  11. Hemostatic effect of 3D-printed hip fixators in children with retinoblastoma after intra-arterial chemotherapy: a non-randomized controlled trial.2024Scientific reportsFree full text
  12. Factors influencing parental fatigue in children with retinoblastoma based on the unpleasant symptoms theory.2024Scientific reportsFree full text
  13. Risk factors for cataract in retinoblastoma management.2024The British journal of ophthalmologyFree full text
  14. Correlating somatic copy number alteration in aqueous humour cfDNA with chemotherapy history, eye salvage and pathological features in retinoblastoma.2024The British journal of ophthalmologyFree full text
  15. NSUN2-mediated m5 C RNA methylation dictates retinoblastoma progression through promoting PFAS mRNA stability and expression.2023Clinical and translational medicineFree full text
  16. Human Papillomavirus and Retinoblastoma: Evidence From a Systematic Review and Meta-analysis of Cross-Sectional Studies.2023International journal of public healthFree full text
  17. The Use of rAAV2-RB1-Mediated Gene Therapy in Retinoblastoma.2023Investigative ophthalmology & visual scienceFree full text
  18. A novel MYCN-YTHDF1 cascade contributes to retinoblastoma tumor growth by eliciting m6A -dependent activation of multiple oncogenes.2023Science China. Life sciences
  19. Intravenous versus super-selected intra-arterial chemotherapy in children with advanced unilateral retinoblastoma: an open-label, multicentre, randomised trial.2023The Lancet. Child & adolescent health
  20. Contemporary Update of Retinoblastoma in China: Three-Decade Changes in Epidemiology, Clinical Features, Treatments, and Outcomes.2022American journal of ophthalmology
  21. Novel insights into RB1 mutation.2022Cancer letters
  22. Eye-Preserving Therapies for Advanced Retinoblastoma: A Multicenter Cohort of 1678 Patients in China.2022Ophthalmology
  23. Regulation of epigenetic homeostasis in uveal melanoma and retinoblastoma.2022Progress in retinal and eye research
  24. Monitoring Retinoblastoma by Machine Learning of Aqueous Humor Metabolic Fingerprinting.2022Small methods
  25. Risk factors for ophthalmic artery stenosis and occlusion in patients with retinoblastoma treated with intra-arterial chemotherapy.2022The British journal of ophthalmologyFree full text
  26. Hope level and associated factors among parents of retinoblastoma patients during COVID-19 pandemic: a cross-sectional study.2021BMC psychiatryFree full text
  27. Single-cell transcriptome profiling reveals intratumoural heterogeneity and malignant progression in retinoblastoma.2021Cell death & diseaseFree full text
  28. Clinical characteristics and germline mutation spectrum of RB1 in Chinese patients with retinoblastoma: A dual-center study of 145 patients.2021Experimental eye research
  29. Xanthatin Selectively Targets Retinoblastoma by Inhibiting the PLK1-Mediated Cell Cycle.2021Investigative ophthalmology & visual scienceFree full text
Chinese-language papers (not in the count)1
  1. [Metachronous bilateral retinoblastoma: a case report].2024[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
Earlier papers (2016–2020)4
  1. LncRNA CANT1 suppresses retinoblastoma progression by repellinghistone methyltransferase in PI3Kγ promoter.2020Cell death & disease
  2. A novel LncRNA transcript, RBAT1, accelerates tumorigenesis through interacting with HNRNPL and cis-activating E2F3.2020Molecular cancer
  3. Dynamic chromosomal tuning of a novel GAU1 lncing driver at chr12p13.32 accelerates tumorigenesis.2018Nucleic acids research
  4. [Pay attention to the application of the international intraocular retinoblastoma classification and sequential multiple modality treatment].2017[Zhonghua yan ke za zhi] Chinese journal of ophthalmology
All its trials on ClinicalTrials.gov, any status1
  1. A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Injection in the Treatment of RetinoblastomaStatus unknownNCT04990271Study sitePhase 2Start 2021-07

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led 15 of the 2,257 English-language PubMed papers on osteosarcoma with an author in mainland China, 2021–2025: 0.7%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 3320212022: 1120222023: 4420232024: 3320242025: 442025

45 hospitals in Shanghai for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyPathology / laboratory medicine

Over half of these papers are lab or animal studies.

Papers it led15
  1. Tumor microenvironment-activated ROS enhancers for effective inhibition of osteosarcoma.2025BMC biotechnologyFree full text
  2. Malignant transformation of craniofacial fibrous dysplasia: A clinicopathological, immunohistochemical and molecular analysis of 15 cases in one single institution.2025Journal of stomatology, oral and maxillofacial surgery
  3. Nanohydroxyapatite-Stabilized Pickering-Emulsion-Incorporated Hydrogel Prevents Postoperative Osteosarcoma Recurrence and Promotes Bone Repair.2025Nano letters
  4. Prognostic factors of head and neck osteosarcoma: A 10-year retrospective study from a single institute.2025Oral oncology
  5. Photothermal-Triggered Extracellular Matrix Clearance and Dendritic Cell Maturation for Enhanced Osteosarcoma Immunotherapy.2024ACS applied materials & interfaces
  6. Head and Neck Osteosarcoma: Perineural Invasion is Associated With Disease-Free Survival and Tumor Metastasis.2024Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  7. Real-world impact of chemotherapy on overall survival in craniomaxillofacial osteosarcoma.2024Journal of stomatology, oral and maxillofacial surgery
  8. DDRGK1 Enhances Osteosarcoma Chemoresistance via Inhibiting KEAP1-Mediated NRF2 Ubiquitination.2023Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  9. EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis.2023BiomoleculesFree full text
  10. Osteosarocma progression in biomimetic matrix with different stiffness: Insights from a three-dimensional printed gelatin methacrylamide hydrogel.2023International journal of biological macromolecules
  11. Secreted phosphoprotein 24 kD (Spp24) inhibits the growth of human osteosarcoma through the BMP-2/Smad signaling pathway.2023Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  12. Camouflage orthodontic treatment combined with genioplasty distraction osteogenesis for skeletal class II relationship secondary to osteosarcoma excision surgery.2022Journal of esthetic and restorative dentistry : official publication of the American Academy of Esthetic Dentistry ... [et al.]
  13. Ultrathin 2D Inorganic Ancient Pigment Decorated 3D-Printing Scaffold Enables Photonic Hyperthermia of Osteosarcoma in NIR-II Biowindow and Concurrently Augments Bone Regeneration.2021Advanced science (Weinheim, Baden-Wurttemberg, Germany)Free full text
  14. Polydopamine-coated UiO-66 nanoparticles loaded with perfluorotributylamine/tirapazamine for hypoxia-activated osteosarcoma therapy.2021Journal of nanobiotechnologyFree full text
  15. FOXP1 drives osteosarcoma development by repressing P21 and RB transcription downstream of P53.2021Oncogene
Chinese-language papers (not in the count)1
  1. [Clincopathological analysis of 171 patients with osteochondroma and malignant transformation in maxillofacial bone].2024Shanghai kou qiang yi xue = Shanghai journal of stomatology
Earlier papers (2016–2020)22
  1. Diffusion Kurtosis Imaging as a Prognostic Marker in Osteosarcoma Patients with Preoperative Chemotherapy.2020BioMed research international
  2. A population-based propensity-matched study of regional dissections in patients with metastatic osteosarcoma.2020Journal of orthopaedic surgery and research
  3. P-Glycoprotein Overexpression Is Associated With Cisplatin Resistance in Human Osteosarcoma.2019Anticancer research
  4. SNHG16 promotes osteosarcoma progression and enhances cisplatin resistance by sponging miR-16 to upregulate ATG4B expression.2019Biochemical and biophysical research communications
  5. HDAC2-mediated upregulation of IL-6 triggers the migration of osteosarcoma cells.2019Cell biology and toxicology
  6. Histone methyltransferase NSD2 regulates apoptosis and chemosensitivity in osteosarcoma.2019Cell death & disease
  7. Elevated H3K27me3 levels sensitize osteosarcoma to cisplatin.2019Clinical epigenetics
  8. Bone morphogenetic protein-2 promotes osteosarcoma growth by promoting epithelial-mesenchymal transition (EMT) through the Wnt/β-catenin signaling pathway.2019Journal of orthopaedic research : official publication of the Orthopaedic Research Society
  9. Autophagy inhibition enhances celecoxib-induced apoptosis in osteosarcoma.2018Cell cycle (Georgetown, Tex.)
  10. CXCR1/Akt signaling activation induced by mesenchymal stem cell-derived IL-8 promotes osteosarcoma cell anoikis resistance and pulmonary metastasis.2018Cell death & disease
  11. Zoledronic Acid: Pleiotropic Anti-Tumor Mechanism and Therapeutic Outlook for Osteosarcoma.2018Current drug targets
  12. MiR-127-3p inhibits cell growth and invasiveness by targeting ITGA6 in human osteosarcoma.2018IUBMB life
  13. Baicalin induces apoptosis in human osteosarcoma cell through ROS-mediated mitochondrial pathway.2018Natural product research
  14. The expression significance of serum MiR-21 in patients with osteosarcoma and its relationship with chemosensitivity.2017European review for medical and pharmacological sciences
  15. Chemotherapy in head and neck osteosarcoma: Adjuvant chemotherapy improves overall survival.2017Oral oncology
  16. Dryofragin inhibits the migration and invasion of human osteosarcoma U2OS cells by suppressing MMP-2/9 and elevating TIMP-1/2 through PI3K/AKT and p38 MAPK signaling pathways.2016Anti-cancer drugs
  17. Tectorigenin inhibits osteosarcoma cell migration through downregulation of matrix metalloproteinases in vitro.2016Anti-cancer drugs
  18. Post-operative hemimaxillectomy rehabilitation using prostheses supported by zygoma implants and remaining natural teeth.2016Clinics (Sao Paulo, Brazil)
  19. Mesenchymal stem cells promote osteosarcoma cell survival and drug resistance through activation of STAT3.2016Oncotarget
  20. Osteosarcoma of head and neck: A retrospective study on prognostic factors from a single institute database.2016Oral oncology
  21. Osteosarcoma of the Mandible: A Site-Specific Study on Survival and Prognostic Factors.2016The Journal of craniofacial surgery
  22. TIMP3 regulates osteosarcoma cell migration, invasion, and chemotherapeutic resistances.2016Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine

Run the PubMed searchClinicalTrials.gov

Cancer

Gastrointestinal stromal tumour

胃肠道间质瘤

Led 1 of the 523 English-language PubMed papers on gastrointestinal stromal tumour with an author in mainland China, 2021–2025: 0.2%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 1120222023: 0020232024: 0020242025: 002025

21 hospitals in Shanghai for gastrointestinal stromal tumour240 hospitals in China for gastrointestinal stromal tumour

No open trial on gastrointestinal stromal tumour lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersSurgery (general/hepatobiliary/pancreatic)

Run the PubMed searchClinicalTrials.gov

Cancer

Neuroblastoma

神经母细胞瘤

Led 2 of the 1,132 English-language PubMed papers on neuroblastoma with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 1120242025: 002025

27 hospitals in Shanghai for neuroblastoma321 hospitals in China for neuroblastoma

No open trial on neuroblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersMedical oncology

Run the PubMed searchClinicalTrials.gov

Blood disorders

Lymphoma

淋巴瘤

Led 22 of the 3,830 English-language PubMed papers on lymphoma with an author in mainland China, 2021–2025: 0.6%.

Papers led
22
2021–2025
Trials led
1
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 5520212022: 4420222023: 6620232024: 5520242025: 222025

20 hospitals in Shanghai for lymphoma199 hospitals in China for lymphoma

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Recruiting
    The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and Radiotherapy
    Phase
    Phase 2
    Started
    2023-11
    Posted
    Registry
    NCT06503276

    Age 18 years to 75 years (registered criteria)

    Led by Shanghai Ninth People's HospitalShanghai

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmologyPathology / laboratory medicineRadiology / nuclear medicineMedical oncology
Papers it led22
  1. A Stepwise decision tree model for differential diagnosis of Kimura's disease in the head and neck.2025BMC medical imagingFree full text
  2. Serum metabolic patterns reveal the diagnostic and prognostic role of alanine abnormality in ocular adnexal lymphoma.2025Proceedings of the National Academy of Sciences of the United States of AmericaFree full text
  3. Role of allogeneic hematopoietic stem cell transplantation in patients with high-risk T-cell lymphoblastic leukaemia/lymphoma: an analysis of clinical outcomes.2024Bone marrow transplantation
  4. Prediction model of radiotherapy outcome for Ocular Adnexal Lymphoma using informative features selected by chemometric algorithms.2024Computers in biology and medicine
  5. Non-IG::MYC in diffuse large B-cell lymphoma confers variable genomic configurations and MYC transactivation potential.2024LeukemiaFree full text
  6. A novel lipid metabolism-based risk model associated with immunosuppressive mechanisms in diffuse large B-cell lymphoma.2024Lipids in health and diseaseFree full text
  7. Prognostic factors and clinical survival outcome in patients with primary mediastinal diffuse large B-cell lymphoma in rituximab era: A population-based study.2024MedicineFree full text
  8. MYC-targeted genes predict distant recurrence in patients with ocular adnexal extranodal marginal zone lymphoma.2023Annals of hematology
  9. BeEAM (Bendamustine, Etoposide, Cytarabine, Melphalan) Versus BEAM (Carmustine, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen Before Autologous Haematopoietic Cell Transplantation: A Systematic Review and Meta-Analysis.2023Cell transplantationFree full text
  10. Multi-omics and case-control analyses identify immunoglobulin M as a tumour-derived serum biomarker of ocular adnexal extranodal marginal zone lymphoma.2023Clinical and translational medicineFree full text
  11. Metabolic Reprogramming and Potential Therapeutic Targets in Lymphoma.2023International journal of molecular sciencesFree full text
  12. MALT lymphoma of the head and neck: Surgery alone can be an option.2023Oral oncology
  13. Predicting the risk of distant and local recurrence for patients with ocular adnexal extranodal marginal zone lymphoma: a matched case-control study.2023The British journal of ophthalmology
  14. Loss of LEF-1 expression as a diagnostic indicator for extranodal NK/T-cell lymphoma: An immunohistochemical study of 88 cases.2022European journal of haematology
  15. Proteotranscriptomics of ocular adnexal B-cell lymphoma reveals an oncogenic role of alternative splicing and identifies a diagnostic marker.2022Journal of experimental & clinical cancer research : CRFree full text
  16. Conservative treatment of head and neck lymphoma is not the only effective treatment: A retrospective analysis of 301 cases.2022Oral oncology
  17. A retrospective study to evaluate the CT and MR imaging findings of non-Hodgkin's lymphoma affecting the jaw bones.2022Oral radiology
  18. Downregulation of USP18 reduces tumor-infiltrating activated dendritic cells in extranodal diffuse large B cell lymphoma patients.2021AgingFree full text
  19. Remodeling of the tumor microenvironment using an engineered oncolytic vaccinia virus improves PD-L1 inhibition outcomes.2021Bioscience reportsFree full text
  20. Indicators for Malignant Transformation in Patients With Lymphoepithelial Lesion.2021Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons
  21. Clinicopathological aspects of primary mucosa-associated lymphoid tissue lymphoma of the salivary gland: A retrospective single-center analysis of 72 cases.2021Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology
  22. NFYB potentiates STK33 activation to promote cisplatin resistance in diffuse large B-cell lymphoma.2021Leukemia research
All its trials on ClinicalTrials.gov, any status3
  1. The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyRecruitingNCT06503276Lead sponsorPhase 2Start 2023-11
  2. GELAD Chemotherapy and Sandwiched Radiotherapy in the Treatment of Stage IE/IIE Natural Killer/T-cell LymphomaCompletedNCT02733458Study siteN/AStart 2016-03
  3. MEDA Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation for Stage IV Natural Killer/T-cell LymphomaCompletedNCT02764281Study siteN/AStart 2015-04

Run the PubMed searchClinicalTrials.gov

Blood disorders

Haemophilia A

血友病 A

Led 1 of the 272 English-language PubMed papers on haemophilia A with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

9 hospitals in Shanghai for haemophilia A132 hospitals in China for haemophilia A

No open trial on haemophilia A lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Blood disorders

Fanconi anaemia

范可尼贫血

Led 1 of the 68 English-language PubMed papers on Fanconi anaemia with an author in mainland China, 2021–2025: 1.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

4 hospitals in Shanghai for Fanconi anaemia40 hospitals in China for Fanconi anaemia

No open trial on Fanconi anaemia lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Coronary heart disease

冠心病

Led 15 of the 5,119 English-language PubMed papers on coronary heart disease with an author in mainland China, 2021–2025: 0.3%.

Papers led
15
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 6620212022: 2220222023: 1120232024: 4420242025: 222025

17 hospitals in Shanghai for coronary heart disease231 hospitals in China for coronary heart disease

No open trial on coronary heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Departments in papersMedical oncologyRadiology / nuclear medicine
Papers it led15
  1. Long-term changes in frailty and incident atrial fibrillation, heart failure, coronary heart disease, and stroke: A prospective follow-up study.2025Heart rhythm
  2. Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study.2025Scientific reportsFree full text
  3. Drug-coated balloon therapy for in-stent restenosis in patients with iliofemoral deep vein thrombosis: A single-arm observational study.2024Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
  4. Differences in the Fat Attenuation Index Ratio of Pericoronary Adipose Tissue And Aortic Root Epicardial Adipose Tissue in Various Plaques.2024Current medical imaging
  5. A Mendelian Randomisation Analysis Reveals No Relationship Between Periodontitis and Coronary Atherosclerosis.2024International dental journalFree full text
  6. Analysis of correlative factors of female coronary slow-flow phenomenon: A retrospective study.2024MedicineFree full text
  7. A comparative study of two single-stage oral mucosal substitution urethroplasty (Kulkarni and Asopa) in the surgical treatments of lichen sclerosus urethral strictures.2023Asian journal of andrologyFree full text
  8. Joint exposure to positive affect, life satisfaction, broad depression, and neuroticism and risk of cardiovascular diseases: A prospective cohort study.2022Atherosclerosis
  9. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease.2022BMC cardiovascular disordersFree full text
  10. Nicotine exacerbates atherosclerosis through a macrophage-mediated endothelial injury pathway.2021AgingFree full text
  11. Serum free fatty acids are associated with severe coronary artery calcification, especially in diabetes: a retrospective study.2021BMC cardiovascular disordersFree full text
  12. Long-term night shift work is associated with the risk of atrial fibrillation and coronary heart disease.2021European heart journal
  13. Circulating ANGPTL3 and ANGPTL4 levels predict coronary artery atherosclerosis severity.2021Lipids in health and diseaseFree full text
  14. Predictive and prognostic value of v-set and transmembrane domain-containing 1 expression in monocytes for coronary artery disease.2021Reviews in cardiovascular medicine
  15. Association of Circulating Irisin Levels and the Characteristics and Prognosis of Coronary Artery Disease.2021The American journal of the medical sciences
All its trials on ClinicalTrials.gov, any status3
  1. Clinical and Genetic Characteristics of Coronary Artery Disease in Chinese Young AdultsStatus unknownNCT02496858Study siteStart 2017-05
  2. Clinical Trial on the Efficacy and Safety of Sirolimus-Eluting Stent (MiStent® System)Status unknownNCT02448524Study sitePhase 3Start 2015-07
  3. Acarbose Cardiovascular Evaluation TrialCompletedNCT00829660Study sitePhase 4Start 2009-02

Run the PubMed searchClinicalTrials.gov

Other diseases

Congenital heart disease

先天性心脏病

Led no English-language PubMed papers on congenital heart disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

19 hospitals in Shanghai for congenital heart disease207 hospitals in China for congenital heart disease

No open trial on congenital heart disease lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Scoliosis

脊柱侧弯

Led 2 of the 925 English-language PubMed papers on scoliosis with an author in mainland China, 2021–2025: 0.2%.

Papers led
2
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 2220242025: 002025

12 hospitals in Shanghai for scoliosis107 hospitals in China for scoliosis

No open trial on scoliosis lists this hospital on ClinicalTrials.gov on 18 Nov 2026.

The records behind these numbers
Papers it led2
  1. Clinical features and surgical treatments of scoliosis in neurofibromatosis type 1: a systemic review and meta-analysis.2024European spine journal : official publication of the European Spine Society, the European Spinal Deformity Society, and the European Section of the Cervical Spine Research Society
  2. Teaching NeuroImage: Clinical and Imaging Features of Cobb Syndrome.2024Neurology

Run the PubMed searchClinicalTrials.gov

Other diseases

Takayasu arteritis

大动脉炎

Led no English-language PubMed papers on Takayasu arteritis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

8 hospitals in Shanghai for Takayasu arteritis100 hospitals in China for Takayasu arteritis

No open trial on Takayasu arteritis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. Aneurysms in Takayasu's arteritis: a retrospective study of Chinese patients.2020Clinical and experimental rheumatology

Run the PubMed searchClinicalTrials.gov

Other diseases

Idiopathic pulmonary fibrosis

特发性肺纤维化

Led 4 of the 989 English-language PubMed papers on idiopathic pulmonary fibrosis with an author in mainland China, 2021–2025: 0.4%.

Papers led
4
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 222025

26 hospitals in Shanghai for idiopathic pulmonary fibrosis288 hospitals in China for idiopathic pulmonary fibrosis

No open trial on idiopathic pulmonary fibrosis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

Spinal muscular atrophy

脊髓性肌萎缩症

Led no English-language PubMed papers on spinal muscular atrophy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

6 hospitals in Shanghai for spinal muscular atrophy49 hospitals in China for spinal muscular atrophy

No open trial on spinal muscular atrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Duchenne muscular dystrophy

杜氏肌营养不良

Led 1 of the 213 English-language PubMed papers on Duchenne muscular dystrophy with an author in mainland China, 2021–2025: 0.5%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

11 hospitals in Shanghai for Duchenne muscular dystrophy111 hospitals in China for Duchenne muscular dystrophy

No open trial on Duchenne muscular dystrophy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Behçet disease

白塞病

Led 1 of the 245 English-language PubMed papers on Behçet disease with an author in mainland China, 2021–2025: 0.4%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

14 hospitals in Shanghai for Behçet disease139 hospitals in China for Behçet disease

No open trial on Behçet disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersOphthalmology / neuro-ophthalmology

Run the PubMed searchClinicalTrials.gov

Other diseases

IgA nephropathy

IgA 肾病

Led no English-language PubMed papers on IgA nephropathy in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

23 hospitals in Shanghai for IgA nephropathy300 hospitals in China for IgA nephropathy

No open trial on IgA nephropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)1
  1. miR-200bc/429 cluster alleviates inflammation in IgA nephropathy by targeting TWEAK/Fn14.2017International immunopharmacology

Run the PubMed searchClinicalTrials.gov

Other diseases

Osteogenesis imperfecta

成骨不全症

Led 1 of the 99 English-language PubMed papers on osteogenesis imperfecta with an author in mainland China, 2021–2025: 1.0%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

6 hospitals in Shanghai for osteogenesis imperfecta58 hospitals in China for osteogenesis imperfecta

No open trial on osteogenesis imperfecta lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Primary biliary cholangitis

原发性胆汁性胆管炎

Led no English-language PubMed papers on primary biliary cholangitis in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

16 hospitals in Shanghai for primary biliary cholangitis153 hospitals in China for primary biliary cholangitis

No open trial on primary biliary cholangitis lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
All its trials on ClinicalTrials.gov, any status1
  1. Safety and Efficacy of Tauroursodeoxycholic Acid Versus Ursofalk in the Treatment of Adult Primary Biliary CirrhosisCompletedNCT01857284Study sitePhase 3Start 2009-09

Run the PubMed searchClinicalTrials.gov

Other diseases

Hirschsprung disease

先天性巨结肠

Led no English-language PubMed papers on Hirschsprung disease in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

5 hospitals in Shanghai for Hirschsprung disease76 hospitals in China for Hirschsprung disease

No open trial on Hirschsprung disease lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Earlier papers (2016–2020)2
  1. A homozygous MITF mutation leads to familial Waardenburg syndrome type 4.2019American journal of medical genetics. Part A
  2. Genetic analysis of a Chinese family with members affected with Usher syndrome type II and Waardenburg syndrome type IV.2017International journal of pediatric otorhinolaryngology

Run the PubMed searchClinicalTrials.gov

Other diseases

Inherited epidermolysis bullosa

遗传性大疱性表皮松解症

Led 1 of the 56 English-language PubMed papers on inherited epidermolysis bullosa with an author in mainland China, 2021–2025: 1.8%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 1120232024: 0020242025: 002025

7 hospitals in Shanghai for inherited epidermolysis bullosa41 hospitals in China for inherited epidermolysis bullosa

No open trial on inherited epidermolysis bullosa lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Other diseases

Leber hereditary optic neuropathy

Leber 遗传性视神经病变

Led 1 of the 52 English-language PubMed papers on Leber hereditary optic neuropathy with an author in mainland China, 2021–2025: 1.9%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 0020242025: 112025

3 hospitals in Shanghai for Leber hereditary optic neuropathy30 hospitals in China for Leber hereditary optic neuropathy

No open trial on Leber hereditary optic neuropathy lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

上海交通大学医学院附属第九人民医院

Shanghai Ninth People's Hospital

上海

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR
Suzhou Ninth People's Hospital; Ninth People's Hospital of Chongqing; Chongqing Ninth People's Hospital; Suzhou Ninth People's Hospital Affiliated to Soochow University; Huangpu Branch of the Ninth People's Hospital; Hangzhou Ninth People's Hospital; Bethel Hospital; 上海第九人民医院

Suggest a correctionDownload the data